HK1256017A1 - 用於治療癌症的口服給藥紫杉醇和p-gp抑制劑的治療組合 - Google Patents

用於治療癌症的口服給藥紫杉醇和p-gp抑制劑的治療組合

Info

Publication number
HK1256017A1
HK1256017A1 HK18115067.6A HK18115067A HK1256017A1 HK 1256017 A1 HK1256017 A1 HK 1256017A1 HK 18115067 A HK18115067 A HK 18115067A HK 1256017 A1 HK1256017 A1 HK 1256017A1
Authority
HK
Hong Kong
Prior art keywords
cancer
inhibitor
treatment
orally administered
therapeutic combinations
Prior art date
Application number
HK18115067.6A
Other languages
English (en)
Inventor
Min-Fun Rudolf Kwan
E Douglas Kramer
Geralk J Fetterly
Cheung-Tak Hung
Christopher Glyn Charles Alexander Jackson
Paul William Glue
Original Assignee
Athenex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athenex Therapeutics Ltd filed Critical Athenex Therapeutics Ltd
Publication of HK1256017A1 publication Critical patent/HK1256017A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK18115067.6A 2015-07-21 2018-11-26 用於治療癌症的口服給藥紫杉醇和p-gp抑制劑的治療組合 HK1256017A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562195243P 2015-07-21 2015-07-21
PCT/IB2016/001132 WO2017013490A2 (en) 2015-07-21 2016-07-21 Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer

Publications (1)

Publication Number Publication Date
HK1256017A1 true HK1256017A1 (zh) 2019-09-13

Family

ID=57833861

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18115067.6A HK1256017A1 (zh) 2015-07-21 2018-11-26 用於治療癌症的口服給藥紫杉醇和p-gp抑制劑的治療組合

Country Status (10)

Country Link
US (2) US20180207148A1 (zh)
EP (1) EP3324968B1 (zh)
CN (2) CN115778956A (zh)
AU (3) AU2016295357B2 (zh)
CA (1) CA2993127C (zh)
HK (1) HK1256017A1 (zh)
JO (1) JO3737B1 (zh)
MX (2) MX2018000872A (zh)
TW (1) TWI760306B (zh)
WO (1) WO2017013490A2 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752750B (zh) * 2015-09-30 2022-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
WO2019200290A1 (en) * 2018-04-13 2019-10-17 Athenex Therapeutics Limited Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of angiosarcoma
CA3122699A1 (en) * 2018-12-14 2020-06-18 Athenex HK Innovative Limited Therapeutic combinations of orally administered irinotecan and a p-gp inhibitor for the treatment of cancer
CA3231510A1 (en) * 2021-09-10 2023-03-16 Johnson Yiu-Nam Lau Therapeutic combinations of orally administered paclitaxel, a p-gp inhibitor, and a checkpoint inhibitor for the treatment of solid tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149360A0 (en) * 1999-10-27 2002-11-10 Baker Norton Pharma Method and compositions for administering taxanes orally to human patients
PL373287A1 (en) * 2002-05-07 2005-08-22 Altana Pharma Ag New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
KR100557093B1 (ko) * 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
KR101466245B1 (ko) * 2010-01-15 2014-12-01 한미사이언스 주식회사 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물
US10441544B2 (en) * 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
WO2019200290A1 (en) * 2018-04-13 2019-10-17 Athenex Therapeutics Limited Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of angiosarcoma

Also Published As

Publication number Publication date
JO3737B1 (ar) 2021-01-31
CA2993127C (en) 2023-10-17
EP3324968B1 (en) 2023-09-27
EP3324968A4 (en) 2019-04-10
AU2016295357A1 (en) 2018-02-15
MX2022000394A (es) 2022-02-10
CN108135895A (zh) 2018-06-08
US20230172926A1 (en) 2023-06-08
CN115778956A (zh) 2023-03-14
CA2993127A1 (en) 2017-01-26
US20180207148A1 (en) 2018-07-26
WO2017013490A3 (en) 2017-03-02
TWI760306B (zh) 2022-04-11
WO2017013490A2 (en) 2017-01-26
TW201716064A (zh) 2017-05-16
AU2023229590A1 (en) 2023-10-05
MX2018000872A (es) 2018-08-15
EP3324968A2 (en) 2018-05-30
AU2021209160A1 (en) 2021-08-19
AU2016295357B2 (en) 2021-05-13
EP3324968C0 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
HK1257249A1 (zh) 使用脂質體伊立替康和parp抑制劑用於癌症治療的組合療法
IL272948A (en) ENPP1 inhibitors and their use for cancer treatment
HK1252873A1 (zh) 用於癌症治療和預防的疫苗
HK1247129A1 (zh) 治療癌症的聯合療法
HK1251475A1 (zh) 用於癌症治療的聯合療法
ZA201806819B (en) Pharmaceutical combinations for the treatment of cancer
IL258854A (en) Preparations containing cannabidiol and secondary medicinal agents for cancer treatment
IL251816B (en) A pharmaceutical combination containing avalocidib and a bromodomain (brd) inhibitor for use in the treatment of cancer
SG11202104923YA (en) Pharmaceutical combination for treatment of cancer
PT3487505T (pt) Administração e dosagem de diaminofenotiazinas
DK3148532T3 (en) Pharmaceutical Combination Comprising a CDK Inhibitor and a Thioredoxin Reductase Inhibitor for the Treatment of Cancer
HK1256017A1 (zh) 用於治療癌症的口服給藥紫杉醇和p-gp抑制劑的治療組合
ZA201902090B (en) Combination treatments comprising administration of imidazopyrazinones
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
EP3370773A4 (en) POLYTHERAPY COMPRISING IMMUNOTOXINS AND A CONTROL POINT INHIBITOR
IL258494A (en) Rational combined therapy for cancer treatment
EP3549608A4 (en) USE OF A COMBINATION OF A VEGFR INHIBITOR AND PARP INHIBITOR IN THE MANUFACTURING OF A MEDICINAL PRODUCT FOR TREATMENT OF STOMACH CANCER
ZA201907286B (en) A pharmaceutical combination for the treatment of a cancer
GB201713936D0 (en) Pharmaceutical combinations for the treatment of cancer
EP3315136B8 (en) Cancer therapeutic drug and cancer treatment method
GB201612863D0 (en) Administration and dosage of diaminophenothiazines
GB201515752D0 (en) Combination of galactose and anticancer drugs for cancer treatment